Opinion

Video

Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following question(s):

    • Please discuss your general approach to using neoadjuvant therapy to escalate or deescalate therapy for patients?